The dual SRC-ABL inhibitors in Ph plus acute lymphoblastic leukemia to enhance synergy between targeted BCR-ABL and BCL-2 inhibitors.

被引：0
|
作者：
Leonard, Jessica Taft
Spurgeon, Stephen Edward Forbes
Traer, Elie A.
Hayes-Lattin, Brandon M.
Loriaux, Marc
Tyner, Jeffrey
Druker, Brian J.
Chang, Bill H.
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[3] Doernbecher Childrens Hosp, Portland, OR USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7073
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia
    Leoni, Veronica
    Biondi, Andrea
    HAEMATOLOGICA, 2015, 100 (03) : 295 - 299
  • [2] Targeting BCL-2 and BCR-Abl Activity in Ph plus ALL
    Leonard, Jessica T.
    Traer, Elie
    Hayes-Lattin, Brandon
    Tyner, Jeffrey
    Druker, Brian
    Chang, Bill H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S190 - S190
  • [3] Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance
    Azam, Mohammad
    Nardi, Valentina
    Shakespeare, William C.
    Metcalf, Chester A., III
    Bohacek, Regine S.
    Wang, Yihan
    Sundaramoorthi, Raji
    Sliz, Piotr
    Veach, Darren R.
    Bornmann, William G.
    Clarkson, Bayard
    Dalgarno, David C.
    Sawyer, Tomi K.
    Daley, George Q.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (24) : 9244 - 9249
  • [4] 2-DEOXY-D-GLUCOSE INDUCES APOPTOSIS IN BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA AND SYNERGIZES WITH BCR/ABL TYROSINE KINASE INHIBITORS
    Barredo, Julio C.
    Leclerc, Guy J.
    Du, Jianfeng
    PEDIATRIC BLOOD & CANCER, 2012, 59 (06) : 1035 - 1035
  • [5] A Screening-Based Approach to Circumvent Tumor Microenvironment-Driven Intrinsic Resistance to BCR-ABL plus Inhibitors in Ph plus Acute Lymphoblastic Leukemia
    Singh, Harpreet
    Shelat, Anang A.
    Singh, Amandeep
    Boulos, Nidal
    Williams, Richard T.
    Guy, R. Kiplin
    JOURNAL OF BIOMOLECULAR SCREENING, 2014, 19 (01) : 158 - 167
  • [6] Targeting BCL6-Mediated Resistance to BCR-ABL Targeted Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL) through the Addition of Histone Deacetylase (HDAC) Inhibitors
    Cohen, Gordon
    Annesley, Colleen E.
    Rau, Rachel E.
    Kelley, Shannon
    Magoon, Daniel
    Brown, Patrick
    BLOOD, 2015, 126 (23)
  • [7] Src, Akt, NF-κB, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia
    Vazquez-Franco, Jose E.
    Reyes-Maldonado, Elba
    Vela-Ojeda, Jorge
    Dominguez-Lopez, Maria L.
    Lezama, Ruth A.
    LEUKEMIA RESEARCH, 2012, 36 (07) : 862 - 867
  • [8] Kinase domain point mutations in Ph plus acute lymphoblastic leukemia (ALL) and lymphoid blast crisis of chronic myeloid leukemia (CML) and their emergence following therapy with Bcr-Abl kinase inhibitors.
    Jones, Dan
    Luthra, Rayjalakshmi
    Kantarjian, Hagop M.
    Breeden, Megan
    O'Brien, Susan
    Faderl, Stefan
    Cortes, Jorge
    Thomas, Deborah
    BLOOD, 2006, 108 (11) : 519A - 519A
  • [9] Overcoming Leukemia-Induced Immune Suppression in BCR-ABL plus Acute Lymphoblastic Leukemia
    Farrar, Michael
    Hekim, Can
    Luke, Manlove S.
    Vezys, Vaiva
    Jenkins, Marc K.
    BLOOD, 2017, 130
  • [10] T-Cell Suppression By Src/ABL Kinase Inhibitors When Combined with Blinatumomab in Ph plus Acute Lymphoblastic Leukemia
    Leonard, Jessica
    Kosaka, Yoko
    Malla, Pavani
    Hayes-Lattin, Brandon
    Lamble, Adam J.
    Druker, Brian J.
    Tyner, Jeffrey W.
    Chang, Bill H.
    Lind, Evan F.
    BLOOD, 2018, 132
12345